# IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Source: https://onco.cc/trials/nct05551507/  
OnCo record `nct05551507` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IN10018 in ovarian cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.

## Summary

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer is a phase 1/2 interventional study registered as NCT05551507 by InxMed (Shanghai) Co., Ltd., with 150 participants planned, started 2020-07-27 and due to reach its primary completion in 2026-05-31. Interventions recorded: IN10018 in combination with PLD. Conditions listed: Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05551507
- Phase: 1/2
- Setting: A Phase Ib/II, Open-label Clinical Study to Evaluate the Safety, Tolerability and Antitumor Activities of IN10018 in Combination With Standard Chemotherapy in Subjects With High-grade Serous Epithelial Ovarian Cancer
- Sponsor: InxMed (Shanghai) Co., Ltd.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT05551507: https://clinicaltrials.gov/study/NCT05551507

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [IN10018](https://onco.cc/drugs/in10018/)
- companies: [InxMed (Shanghai)](https://onco.cc/companies/inxmed-shanghai/)

---
JSON: https://onco.cc/api/v1/entities/nct05551507.json